Tezepelumab — Drug Intelligence | 15 EU Trials

Filter these 15 trials by condition, phase, country and more.

Open in Search →

15 Registered trials

8 Recruiting

3 Completed trials

8 Sponsors

18 Countries

Phase III

Phase II

Phase IV

Phase III: 8 Phase II: 4 Phase IV: 3

Oversight events:

2 serious breaches 2 temporary halts across 2 trials

View oversight register →

Indications tested

Asthma 4 Chronic obstructive pulmonary disease 2 Idiopathic pulmonary fibrosis 1 Chronic rhinosinusitis with nasal polyps 1

Sponsors using this IMP

AstraZeneca AB 7 Medical University Of Vienna 2 Amsterdam UMC Stichting 1 Centre Hospitalier Universitaire De Nantes 1 Hospital Foch 1 Imperial College London Limited 1 Philipps-Universitaet Marburg 1 Region Hovedstaden 1

All trials

15 total

A RAndomised Placebo Controlled Trial - to Explore the Efficacy and Mechanism of Action of Tezepelumab in EGPA- RACE-MATE Not authorised

2024-514794-22-01 Phase II 1 country Imperial College London Limited
DIRECTION Study Pending

2025-524495-39-00 Phase IV 1 country Medical University Of Vienna
BIOlogical treatment GRAdual Interval Longing in severe Asthma (BIO-GRAIL) Pending

2025-524741-28-00 Phase IV 1 country Amsterdam UMC Stichting
Efficacy of an anti-TSLP monoclonal antibody in the management of chronic bronchial disease induced by bronchiolitis obliterans syndrome in … Recruiting

2024-516796-33-00 Phase II 1 country Hospital Foch
TezeBarrier Study Recruiting

2024-517538-16-00 Phase IV 1 country Medical University Of Vienna
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmona… Recruiting

2024-517458-90-00 Phase III 7 countries AstraZeneca AB
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmona… Recruiting

2024-517457-27-00 Phase III 9 countries AstraZeneca AB
A study to investigate changes in symptoms in adult participants with chronic rhinosinusitis with nasal polyposis initiating treatment with … Recruiting

2024-513862-20-00 Phase III 7 countries AstraZeneca AB
Effects of blocking TSLP on airway inflammation and the epithelial immune-response to exacerbation triggers in patients with COPD A randomiz… Recruiting

2024-511730-12-00 Phase II 1 country Region Hovedstaden
A study to investigate the efficacy and safety of tezepelumab compared with placebo in children 5 to < 12 years old with severe asthma Recruiting

2022-502984-39-00 Phase III 7 countries AstraZeneca AB
REVERT : REVErsing airway Remodelling with Tezepelumab Recruiting

2024-513195-18-00 Phase III 1 country Centre Hospitalier Universitaire De Montpellier
An open-label study to assess reduction of daily asthma medication with tezepelumab in patients 12 to 80 years of age with severe asthma Ended

2024-512113-41-00 Phase III 7 countries AstraZeneca AB
A study to investigate changes in symptoms and esophageal histology with tezepelumab compared with placebo in patients aged 12 to 80 years o… Ended

2023-504277-20-00 Phase III 13 countries AstraZeneca AB
Tezepelumab (Anti-TSLP-mab) in progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia - A prospective two-ar… Halted

2024-510884-51-00 Phase II 1 country Philipps-Universitaet Marburg
Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma Ended

2023-504648-33-00 Phase III 2 countries AstraZeneca AB

Showing 1–15 of 15 trials

← All drugs A–Z